The molecular basis underlying Glioblastoma (GBM) heterogeneity and plasticity are not 26 fully understood. Using transcriptomic data of patient-derived brain tumor stem cell lines 27 (BTSCs), classified based on GBM-intrinsic signatures, we identify the AP-1 28 transcription factor FOSL1 as a master regulator of the mesenchymal (MES) subtype. We 29 provide a mechanistic basis to the role of the Neurofibromatosis type 1 gene (NF1), a 30 negative regulator of the RAS/MAPK pathway, in GBM mesenchymal transformation 31 through the modulation of FOSL1 expression. Depletion of FOSL1 in NF1-mutant human 32 BTSCs and Kras-mutant mouse neural stem cells results in loss of the mesenchymal gene 33 signature, reduction in stem cell properties and in vivo tumorigenic potential. Our data 34 demonstrate that FOSL1 controls GBM plasticity and aggressiveness in response to NF1 35 alterations. 36 37 Keywords 38 GBM, Mesenchymal, NF1, FOSL1, FRA-1, master regulator 39 40 Significance 41
Introduction 51
Glioblastoma (GBM), the most common and aggressive primary brain tumor in 52 adults, is characterized by high molecular and cellular inter-and intra-tumoral Nevertheless, the mechanisms of regulation of MES GBMs are still not fully understood. 67
For example, whether the MES transcriptional signature is controlled through tumor cell-68 intrinsic mechanisms or influenced by the tumor microenvironment (TME) is still an 69 unsolved question. In fact, the critical contribution of the TME adds another layer of 70 complexity to MES GBMs. Tumors from this subtype are highly infiltrated by non-71 neoplastic cells, as compared to PN and CL subtypes (Wang et al., 2017) . Additionally, 72 MES tumors express high levels of angiogenic markers and exhibit high levels of necrosis 73 (Cooper et al., 2012) . 74
Even though each subtype is associated with specific genetic alterations, there is 75 a considerable plasticity among them: different subtypes co-exist in the same tumors and 76 shifts in subtypes can occur over time (Patel et al., 2014; Sottoriva et al., 2013) . This 77 plasticity may be explained by acquisition of new genetic and epigenetic abnormalities, 78 by stem-like reprogramming or by clonal variation (Fedele et al., 2019) . It is also not fully 79 understood whether the distinct subtypes evolve from a common glioma precursor 80 (Ozawa et al., 2014) . For instance, PN tumors often switch phenotype to MES upon 81 recurrence, and treatment also increases the mesenchymal gene signature, suggesting that 82 Figure 1A) . Differential gene expression analysis comparing MES 120 versus Non-MES (PN and CL) BTSCs confirmed a clear separation among the two 121 groups, with the exception of a small number of cell lines that showed a mixed expression 122 profile ( Figure 1B and Table S2 ). 123
To reveal the signaling pathways underlying the differences among MES versus 124
Non-MES BTSCs we then applied a network-based approach based on ARACNe 125 (Algorithm for the Reconstruction of Accurate Cellular Networks) (Basso et al., 2005; 126 Carro et al., 2010), which identifies a list of transcription factors (TFs) with their predicted 127 targets, defined as regulons. The regulon for each TF is constituted by all the genes whose 128 expression data exhibit significant mutual information with that of a given TF and are 129 thus expected to be regulated by that TF ( the highest enrichment score ( Figure 1C and Figure S1B ). 140
We then analyzed the TCGA pan-glioma dataset (Ceccarelli et al., 2016) and 141 observed that FOSL1 expression is elevated in the IDH-wt glioma molecular subtype 142 ( Figure 1E and Table S4 ) and that high expression levels are associated with worse 143 prognosis in IDH-wt GBM ( Figure 1F ), thus suggesting that FOSL1 could represent not 144 only a master regulator of the glioma-intrinsic MES signature, but also a putative key 145 player in MES GBM pathogenesis. We initially grouped, according to the previously described subtype-specific gene 153 signatures, a subset of IDH-wt GBM samples of the TCGA dataset for which RNA-seq 154 data were available (n = 152) (see methods for details). By analyzing the frequency of 155 NF1 alterations (either point mutations or biallelic gene loss) in the different subtypes 156 (Figure 2A ), we confirmed a significant enrichment of NF1 alterations in MES versus 157
Non-MES tumors (Fisher's Exact test P value = 0.03) ( Figure 2B ). Importantly, we 158 detected higher level of FOSL1 mRNA in the cohort of patient tumors with NF1 159 alterations, both low-grade gliomas (LGGs) and GBMs (Figures 2C and To test whether NF1 signaling is directly involved in the regulation of FOSL1 and 163 the MES subtype, we manipulated NF1 expression in patient derived tumorspheres of 164 either the MES or PN subtype ( Figure S3A Furthermore, analysis of a RAS-induced oncogenic signature expression by GSEA 171 showed a strong reduction in NF1-GRD expressing cells (NES = -1.7; FDR q-value < 172 0.001) ( Figure S2D ). Most importantly, NF1-GRD expression led to a significant 173 reduction of the MGSs (Wang signature: NES = -1.3; FDR q-value = 0.05; Phillips 174 signature: NES = -1.7; FDR q-value < 0.001) ( Figure 2E , left panels). On the contrary, 175
Proneural gene signatures (PNGSs) were upregulated (Wang signature: NES = 1.2; FDR 176 q-value = 0.12; Phillips signature: NES = 1.3; FDR q-value = 0.1) ( Figure 2E , right 177 panels). Western blot analysis also revealed a significant decrease of CHI3L1 expression, 178 a well characterized mesenchymal marker, upon NF1-GRD overexpression ( Figure 2F ). 179
Mesenchymal glioblastoma cells are able to differentiate into osteocytes, a feature 180 they share with mesenchymal stem cells (Ricci-Vitiani et al., 2008; Tso et al., 2006) . 181
Consistent with the loss of the MGS, the ability to differentiate into osteocytes was lost 182 in the BTSC 233 MES cells transduced with the NF1-GRD, as documented by Alizarin 183
Red staining ( Figure 2G ). 184
To further confirm whether NF1 deletion could be sufficient to induce changes in 185 the MGS, we then knocked down NF1 in the NF1-expressing PN cell line BTSC 3021 186 ( Figure 2H ) and performed microarray gene expression analysis followed by GSEA. Both 187 Wang and Phillips MGSs were enriched upon NF1 silencing (Wang: NES = 1.61; FDR 188 q-value = 0.005; Phillips: NES = 1.9; FDR q-value < 0.001) ( Figure 2I ). The PNGSs 189 instead were not significantly lost (data not shown). 190
Taken together, our data indicate that NF1 modulation is able to alter the MGS 191 expression in GBM. NF1-led gene expression changes might be driven by an effect on 192 MGS master regulators. Alternatively, other TFs might be involved. We therefore 193 analyzed the expression of FOSL1 and other previously described mesenchymal TFs 194 Cell viability was significantly decreased in Fosl1 KO cell lines, as compared to 250 sgCtrl ( Figure 4A ). Concomitantly, we observed a significant decreased percentage of 251 cells in S-phase (mean values: sgCtrl = 42.6%; sgFosl1_1 = 21.6%, P ≤ 0.001; sgFosl1_3 252 = 20.4%, P = 0.003) and an increase in percentage of cells in G2/M (mean values: sgCtrl 253 = 11.7%, sgFosl1_1 = 28.4%, P ≤ 0.001; sgFosl1_3 = 23.4%, P = 0.012) ( Figure 4B ). 254
Another aspect that contributes to GBM aggressiveness is its heterogeneity, 255 attributable in part to the presence of glioma stem cells. By using limiting dilution assays, 256
we found that Fosl1 is required for the maintenance of stem cell capacity ( Figure 4C ). 257
Moreover, RNA-seq analysis showed that sgFosl1_1 cells downregulated the expression 258 of stem genes (Elf4, Klf4, Itgb1, Nes, Sall4, L1cam, Melk, Cd44, Myc, Fut4, Cxcr4, 259 Prom1) while upregulating the expression of lineage-specific genes: neuronal (Map2, 260
Ncam1, Tubb3, Slc1a2, Rbfox3, Dcx), astrocytic (Aldh1l1, Gfap, S100b, Slc1a3) and 261 oligodendrocytic (Olig2, Sox10, Cnp, Mbp, Cspg4) ( Figure 4D ). The different expression 262 of some of the stem/differentiation markers was confirmed also by immunofluorescence 263 analysis. While Fosl1 KO cells presented low expression of the stem cell marker CD44, 264 differentiation markers as GFAP and OLIG2 were significantly higher when compared to 265 sgCtrl cells ( Figure 4E , Figure S4 ). 266
We then sought to test whether: i) p53-null Kras G12V NSCs were tumorigenic and 267 ii) Fosl1 played any role in their tumorigenic potential. Intracranial injections of p53-null 268
Kras G12V NSCs in nu/nu mice led to the development of high-grade tumors with a median 269 survival of 37 days in control cells (n=9). However, the sgFosl1_1 injected mice (n=6) 270 had a significant increase in median survival (54.5 days, Log-rank P = 0.0263) ( In order to investigate if the MES phenotype induced with Fosl1 overexpression 304 would have any effect in vivo, p53-null Kras G12V Fosl1 tetON NSCs were intracranially 305 injected into syngeneic C57BL/6J wildtype mice. Injected mice were randomized and 306 subjected to Dox diet (food pellets and drinking water) or kept as controls with regular 307 food and drinking water with 1% sucrose. No differences in mice survival were observed 308 ( Figure S5B ). However, tumors developed from Fosl1 overexpressing mice (+Dox) were 309 larger ( Figure 5D ), more infiltrative and with a more aggressive appearance than controls 310 (-Dox), that mostly grew as superficial tumor masses, even if both -Dox and +Dox 311 tumors seem to proliferate similarly ( Figure S5C ). 312
Tumorspheres were derived from -Dox and +Dox tumor-bearing mice and Fosl1 313 expression was manipulated in vitro through addition or withdrawal of Dox from the 314 culture medium. In the case of tumorspheres derived from a -Dox tumor, when Dox was 315 added for 19 days, high levels of FRA-1 expression were detected by western blot ( Figure 6D ). Moreover, FOSL1 silencing resulted 343 also in the significant downregulation of the MES genes ( Figure 6E ), while no major 344 differences in the expression of PN genes was observed ( Figure S6B) . 345
Lastly, we tested whether FRA-1 modulates the MGS via direct target regulation. 346
To this end, we first identified high-confidence FOSL1/FRA-1 binding sites in chromatin 347 immunoprecipitation-seq (ChIP-seq) generated in non-mesenchymal cancer cells (see 348 methods) and then we determined the counts per million reads (CPM) of the enhancer 349 histone mark H3K27Ac in a set of MES and non-MES BTSCs (Mack et al., 2019) . 2017). The fact that the enriched macrophage/microglia microenvironment is also able to 418 modulate a MES phenotype suggests that there might be a two-way interaction between 419 tumor cells and TME. The mechanisms of NF1-regulated chemotaxis and whether this 420 relationship between the TME and MGS in GBM is causal remain elusive. 421
Here we provide evidence that manipulation of NF1 expression levels in patient-422 derived BTSCs has a direct consequence on the tumor-intrinsic MGS activation and that 423 such activation, can at least in part be mediated by the modulation of FOSL1. Among the 424 previously validated MRs, only CEBPB appears also to be finely modulated by NF1 425 inactivation. This suggests that among the TFs previously characterized (such as FOSL2, 426 STAT3, BHLHB2 and RUNX1), FOSL1 and CEBPB might play a specific role in the NF1-427 mediated MES transition that occurs in glioma cells with limited or possibly absent effect 428 by the TME. However, whether FOSL1 contributes also to the putative cross-talk between 429 the TME and the cell-intrinsic MGS, will still have to be established. 430
Furthermore we show that FOSL1 is a crucial player in glioma pathogenesis, 431 particularly in a MAPK-driven MES GBM context. Our findings broaden its previously 432 We would like to thank Álvaro Ucero for his input on the project and Flora A. 
Vectors, virus production and infection 585
Flag-tagged NF1-GRD (aminoacids 1131-1534) was amplified by PCR from 586 human cortical tissue (epilepsy patient) and first cloned in the pDRIVE vector. Primers 587 are listed in Table S5 . The NF1-GRD sequence was then excised by restriction digestion 588 using PmeI and SpeI enzymes and subcloned in the modified pCHMWS lentiviral vector 589 (kind gift from V. Baekelandt, University of Leuven, Belgium) sites by removing the 590 fLUC region. The correct sequence was verified by sequencing. For NF1 silencing, NF1 591 short hairpin from pLKO (Sigma, TRCN0000238778) vector was subcloned in pGIPZ 592 lentiviral vector (Open Biosystems). The corresponding short hairpin sequence was 593 synthetized (GATC) and amplified by PCR using XhoI and EcoRI sites containing 594 primers. The PCR product was digested using XhoI and EcoRI and subcloned into the 595 pGIPZ vector previously digested with XhoI and PmeI following by digestion with 596
EcoRI. The two vector fragments were ligated with NF1 short hairpin fragment. The 597 correct insertion and sequence was validated by sequencing. In addition, experiments 598 were performed using shNF1-pGIPZ clone V2LHS_76027 (clone 4) and V2LHS_260806 599 (clone 5). 600 Active Ras pull down assay was performed using Active Ras pull down assay kit 788 (ThermoFisher Scientific #16117) according to the manufacturer's instructions. Briefly, 789 cells were grown in 10 cm plates at 80-90% confluency in presence or absence of growth 790 factors (EGF, FGF and LIF), and lysed with the provided buffer. Lysates were incubated 791 with either GDP or GTP for 30 min followed by precipitation with GST-Raf1-RBD. 792
RCAS viruses (RCAS-shNf1, RCAS-sgNf1 and RCAS-Kras
Western blot was performed with the provided anti-RAS antibody (1:250). experiments are presented as mean ± SD (n=3). Student's t test, relative to sgCtrl: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. C) A representative limiting dilution experiment on p53-null Kras G12V sgCtrl and sgFosl1_1 NSCs, calculated with extreme limiting dilution assay (ELDA) analysis; P < 0.0001. D) Heatmap of expression of stem cell (yellow) and lineage-specific (neuronal -purple, astrocytic -green and oligodendrocyticorange) genes, comparing sgCtrl and sgFosl1_1 p53-null Kras G12V NSCs. E) Quantification of pixel area (fold change relative to sgCtrl) of CD44, GFAP and OLIG2 relative to DAPI pixel area per field of view in control and Fosl1 KO p53-null Kras G12V NSCs. Data from a representative of two independent experiments; Student's t test, relative to sgCtrl: ***P ≤ 0.001. F) Kaplan-Meier survival curves of nu/nu mice injected with p53-null Kras G12V sgCtrl (n=9) and sgFosl1_1 (n=6) NSCs. Log-rank P = 0.0263. G) Western blot analysis using the indicated antibodies of 4 sgCtrl and 4 sgFosl1_1 tumors (showing low or no detectable expression of FRA-1); Vinculin used as loading control. H) Representative images of IHCs using the indicated antibodies. Scale bars represent 100 µm. I) mRNA expression of MES genes in the samples sgCtrl-T4 (higher FRA-1 expression) and sgFosl1_1-T3 and -T4 (no detectable FRA-1 expression). J) mRNA expression of PN genes in samples as in (H). Data from a representative of two experiments are presented as mean ± SD (n=3), normalized to Gapdh expression. Student's t test for sgFosl1_1 tumors, relative to sgCtrl-T4: ns = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. See also Figure S4 . 
IRES-EGFP
; Col1a1 TetO-Fosl1 mice, upon in vitro infection with Cre and induction of Fosl1 overexpression with 1 µg/mL Dox for 72 h; Vinculin used as loading control. B) mRNA expression of Fosl1 and MES genes in Fosl1 tetON p53-null Kras G12V cells upon 72 h induction with 1 µg/mL Dox. C) mRNA expression of PN genes in Fosl1 tetON p53-null Kras G12V cells upon 72 h induction with 1 µg/mL Dox. D) Quantification of tumor area (µm 2 ) of -Dox and +Dox tumors (n=8/8). For each mouse, the brain section on the H&E slide with a larger tumor was considered and quantified using the ZEN software (Zeiss). E) Western blot detection of FRA-1 expression in tumorspheres derived from a control (−Dox) tumor. Tumorspheres were isolated and kept without Dox until first passage, when 1 µg/mL Dox was added and kept for 19 days (+Dox in vitro). F) mRNA expression of Fosl1 and MES genes in tumorspheres in absence or presence of Dox for 19 days. G) mRNA expression of PN genes in tumorspheres in absence or presence of Dox for 19 days. H) Western blot detection of FRA-1 expression in tumorspheres derived from a Fosl1 overexpressing (+Dox) tumor. Tumorspheres were isolated and kept with 1 µg/mL Dox until first passage, when Dox was removed for 19 days (−Dox in vitro). I) mRNA expression of Fosl1 and MES genes in tumorspheres in presence or absence of Dox for 19 days. J) mRNA expression of PN genes in tumorspheres in presence or absence of Dox for 19 days. qPCR data from a representative of two experiments are presented as mean ± SD (n=3), normalized to Gapdh expression. Student's t test, relative to the respective control (−Dox in B, C, F and G; +Dox in I and J): ns = not significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. See also Figure S5 . 
